A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma
This is a single-center, non-randomized study to evaluate the safety and efficacy of C-CAR088 in relapsed or refractory multiple myeloma patients.
Multiple Myeloma
DRUG: C-CAR088
The Incidence of adverse events (TEAEs) within 30 days after intravenous infusion of C-CAR088, 30 days
Overall response rate (ORR), ORR(including sCR / CR / VGPR / PR, based on IMWG 2016 efficacy evaluation criteria), 12 months|Progression free survival (PFS), PFS(based on IMWG 2016 efficacy evaluation criteria), 6 months#12 months
The study will include the following sequential phases: Screening, Apheresis, Baseline, Pre-Treatment (Cell Product Preparation, Lymphodepleting Chemotherapy), C-CAR088 infusion and Follow-up Visit.